Form 4: Unity Biotechnology CEO Sells Shares to Cover Tax Obligations

Anirvan Ghosh, CEO of Unity Biotechnology, sold 642 shares of common stock on February 4, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On February 4, 2025, Anirvan Ghosh, the CEO of Unity Biotechnology, sold 642 shares of the company's common stock.
• The sale was executed at a price of $2.23 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan.
• The purpose of the sale was to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Ghosh directly owns 75,251 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to a stock sale for tax purposes, which is a neutral event.

Industry Context

Form 4 filings are a routine part of the stock market, especially for publicly traded companies. They are required by the SEC to ensure transparency when company insiders, like CEOs and directors, buy or sell their company's stock. This helps prevent insider trading and keeps the market fair for everyone.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholders, but is unlikely to be significant given the small number of shares involved.

Key Dates